Therapeutic trial of intracisternal human tetanus immunoglobulin in clinical tetanus.
A trial has been conducted of the efficacy of human tetanus immunoglobulin (250 I U) administered intrathecally (intracisternally) in addition to standard treatment (equine antitoxin intravenously, penicillin, anticonvulsants). The trial was analysed sequentially and was stopped for 120 patients when there was no longer any chance of achieving a statistically significant difference in favour of intrathecal administration. The sequential plan was modified during the trial. A prognostic correlation was found between onset of the first symptom and admission to hospital.
D000328:Adult; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage / Q000627:therapeutic use; D007278:Injections, Spinal; D007902:Length of Stay; D008297:Male; D011379:Prognosis; D013742:Tetanus / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D013743:Tetanus Antitoxin / Q000008:administration & dosage / Q000627:therapeutic use*
D007136:Immunoglobulins; D013743:Tetanus Antitoxin